Investigation of nuclear nano-morphology marker as a biomarker for cancer risk assessment using a mouse model.
The development of accurate and clinically applicable tools to assess cancer risk is essential to define candidates to undergo screening for early-stage cancers at a curable stage or provide a novel method to monitor chemoprevention treatments. With the use of our recently developed optical technology--spatial-domain low-coherence quantitative phase microscopy (SL-QPM), we have derived a novel optical biomarker characterized by structure-derived optical path length (OPL) properties from the cell nucleus on the standard histology and cytology specimens, which quantifies the nano-structural alterations within the cell nucleus at the nanoscale sensitivity, referred to as nano-morphology marker. The aim of this study is to evaluate the feasibility of the nuclear nano-morphology marker from histologically normal cells, extracted directly from the standard histology specimens, to detect early-stage carcinogenesis, assess cancer risk, and monitor the effect of chemopreventive treatment. We used a well-established mouse model of spontaneous carcinogenesis--Apc(Min) mice, which develop multiple intestinal adenomas (Min) due to a germline mutation in the adenomatous polyposis coli (Apc) gene. We found that the nuclear nano-morphology marker quantified by OPL detects the development of carcinogenesis from histologically normal intestinal epithelial cells, even at an early pre-adenomatous stage (six weeks). It also exhibits a good temporal correlation with the small intestine that parallels the development of carcinogenesis and cancer risk. To further assess its ability to monitor the efficacy of chemopreventive agents, we used an established chemopreventive agent, sulindac. The nuclear nano-morphology marker is reversed toward normal after a prolonged treatment. Therefore, our proof-of-concept study establishes the feasibility of the SL-QPM derived nuclear nano-morphology marker OPL as a promising, simple and clinically applicable biomarker for cancer risk assessment and evaluation of chemopreventive treatment.
University of Pittsburgh, Department of Medicine and Bioengineering, Biomedical Optical Imaging Laboratory, Pittsburgh, Pennsylvania 15232, USA.
Rajan K
RK
Bista
Shikhar
S
Uttam
Douglas J
DJ
Hartman
Wei
W
Qiu
Jian
J
Yu
Lin
L
Zhang
Randall E
RE
Brand
Yang
Y
Liu
D000818:Animals; D015415:Biomarkers / Q000378:metabolism*; D014408:Biomarkers, Tumor; D002467:Cell Nucleus / Q000378:metabolism*; D004195:Disease Models, Animal; D018450:Disease Progression; D055088:Early Detection of Cancer / Q000379:methods; D004847:Epithelial Cells / Q000166:cytology; D005260:Female; D017491:Genes, APC; D007413:Intestinal Mucosa / Q000378:metabolism; D007421:Intestine, Small / Q000378:metabolism / Q000473:pathology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008954:Models, Biological; D009154:Mutation; D036103:Nanotechnology / Q000379:methods; D009369:Neoplasms / Q000175:diagnosis* / Q000473:pathology*; D012306:Risk; D018570:Risk Assessment; D013997:Time Factors
D015415:Biomarkers; D014408:Biomarkers, Tumor